| Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic … SZ Pavletic, P Martin, SJ Lee, S Mitchell, D Jacobsohn, EW Cowen, ... Biology of Blood and Marrow Transplantation 12 (3), 252-266, 2006 | 459 | 2006 |
| H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element K Hamada, SL Gleason, BZ Levi, S Hirschfeld, E Appella, K Ozato Proceedings of the National Academy of Sciences 86 (21), 8289-8293, 1989 | 363 | 1989 |
| FDA drug approval summaries: oxaliplatin A Ibrahim, S Hirschfeld, MH Cohen, DJ Griebel, GA Williams, R Pazdur The Oncologist 9 (1), 8-12, 2004 | 220 | 2004 |
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report PJ Martin, D Weisdorf, D Przepiorka, S Hirschfeld, A Farrell, JD Rizzo, ... Biology of Blood and Marrow Transplantation 12 (5), 491-505, 2006 | 197 | 2006 |
| Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth CC Kappel, MC Velez-Yanguas, S Hirschfeld, LJ Helman Cancer Research 54 (10), 2803-2807, 1994 | 162 | 1994 |
| Paediatric drug development: the impact of evolving regulations MA Turner, M Catapano, S Hirschfeld, C Giaquinto Advanced drug delivery reviews 73, 2-13, 2014 | 147 | 2014 |
| Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene MH Cohen, S Hirschfeld, SF Honig, A Ibrahim, JR Johnson, JJ O'Leary, ... The oncologist 6 (1), 4-11, 2001 | 147 | 2001 |
| New models for large prospective studies: is there a better way? TA Manolio, BK Weis, CC Cowie, RN Hoover, K Hudson, BS Kramer, ... American journal of epidemiology 175 (9), 859-866, 2012 | 135 | 2012 |
| Improving the value of clinical research through the use of Common Data Elements J Sheehan, S Hirschfeld, E Foster, U Ghitza, K Goetz, J Karpinski, L Lang, ... Clinical Trials 13 (6), 671-676, 2016 | 115 | 2016 |
| A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells. S Hirschfeld, AS Levine, K Ozato, M Protić Molecular and cellular biology 10 (5), 2041-2048, 1990 | 115 | 1990 |
| Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer PatientsGuiding the Optimal Translation C Khanna, C London, D Vail, C Mazcko, S Hirschfeld Clinical cancer research 15 (18), 5671-5677, 2009 | 114 | 2009 |
| Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? EA Richey, EA Lyons, JR Nebeker, V Shankaran, JM McKoy, TH Luu, ... Journal of Clinical Oncology 27 (26), 4398, 2009 | 109 | 2009 |
| Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene. PA Burke, S Hirschfeld, Y Shirayoshi, JW Kasik, K Hamada, E Appella, ... The Journal of experimental medicine 169 (4), 1309-1321, 1989 | 108 | 1989 |
| Global alignment of immunization safety assessment in pregnancy–The GAIA project J Bonhoeffer, S Kochhar, S Hirschfeld, PT Heath, CE Jones, J Bauwens, ... Vaccine 34 (49), 5993-5997, 2016 | 97 | 2016 |
| Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. JH Segars, MS Marks, S Hirschfeld, PH Driggers, E Martinez, JF Grippo, ... Molecular and Cellular Biology 13 (4), 2258-2268, 1993 | 97 | 1993 |
| Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia SL Soignet, WP Tong, S Hirschfeld, RP Warrell Jr Cancer chemotherapy and pharmacology 44 (5), 417-421, 1999 | 87 | 1999 |
| Testing of new agents in childhood cancer preclinical models: meeting summary PJ Houghton, PC Adamson, S Blaney, HA Fine, R Gorlick, M Haber, ... Clinical cancer research 8 (12), 3646-3657, 2002 | 76 | 2002 |
| Assaying for a multiplicity of antigens or antibodies with a detection compound S Hirschfeld US Patent 4,514,508, 1985 | 72 | 1985 |
| Oncology drug development: United States Food and Drug Administration perspective S Hirschfeld, R Pazdur Critical reviews in oncology/hematology 42 (2), 137-143, 2002 | 70 | 2002 |
| Global Research in Paediatrics MA Turner, M Catapano, S Hirschfeld, C Giaquinto Paediatric drug development: the impact of evolving regulations. Adv Drug …, 2014 | 62 | 2014 |
